Sivextro Den europeiske union - norsk - EMA (European Medicines Agency)

sivextro

merck sharp & dohme b.v. - tedizolid fosfat - soft tissue infections; skin diseases, bacterial - antibacterials for systemic use, , other antibacterials - sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and adolescents 12 years of age and older.

Xeljanz Den europeiske union - norsk - EMA (European Medicines Agency)

xeljanz

pfizer europe ma eeig - tofacitinib - leddgikt, reumatoid - immunsuppressive - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 og 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Abboticin 100 mg/ ml Norge - norsk - Statens legemiddelverk

abboticin 100 mg/ ml

amdipharm limited - erytromycinetylsuksinat - granulat til mikstur, suspensjon - 100 mg/ ml

Abboticin 40 mg/ ml Norge - norsk - Statens legemiddelverk

abboticin 40 mg/ ml

amdipharm limited - erytromycinetylsuksinat - granulat til mikstur, suspensjon - 40 mg/ ml

Abboticin 1 g Norge - norsk - Statens legemiddelverk

abboticin 1 g

amdipharm limited - erytromycinlaktobionat - pulver til infusjonsvæske, oppløsning - 1 g

Abboticin ES 500 mg Norge - norsk - Statens legemiddelverk

abboticin es 500 mg

amdipharm limited - erytromycinetylsuksinat - tablett, filmdrasjert - 500 mg

Cefazolin MIP 2 g Norge - norsk - Statens legemiddelverk

cefazolin mip 2 g

mip pharma gmbh - cefazolinnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 2 g

Erythromycin Panpharma 1 g Norge - norsk - Statens legemiddelverk

erythromycin panpharma 1 g

panpharma sa - erytromycinlaktobionat - pulver til infusjonsvæske, oppløsning - 1 g

Gentamicin B. Braun 3 mg/ ml Norge - norsk - Statens legemiddelverk

gentamicin b. braun 3 mg/ ml

orifarm as - gentamicinsulfat - infusjonsvæske, oppløsning - 3 mg/ ml

Gentamicin B. Braun 3 mg/ ml Norge - norsk - Statens legemiddelverk

gentamicin b. braun 3 mg/ ml

orifarm as - gentamicinsulfat - infusjonsvæske, oppløsning - 3 mg/ ml